Vanda Pharmaceuticals is suing the FDA for the third time in 2022 — this time over what the company claims is FDA’s “unlawful” delay in granting a public hearing to Vanda regarding expanding the approval of the company’s sleep disorder drug Hetlioz (tasimelteon) to also include the treatment of jet lag disorder.
Source: Drug Industry Daily